News
First Investment: 2014
EXIT - Nasdaq: LHDXQ
Lucira developed an at-home nucleic acid amplification test for the SARS-Cov2 virus that causes Covid-19, as well as a combined Covid-flu test. Pfizer acquired Lucira’s assets in 2023.
News & Insights
Explore Companies
Radionetics Oncology
Discovering more precise ways to deploy radiopharmaceuticals against solid tumors
DVLP Medicines
Creating a software co-pilot for drug development and a new marketplace for investors and outsourced R&D and manufacturing
Noetik
Using self-supervised machine learning to map the circuit diagram of tumor biology and develop new immunotherapies for cancer
Solu Therapeutics
Advancing precision medicine by combining the efficacy of antibodies with the binding ability of small molecules